The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Identifieur interne : 001605 ( Main/Exploration ); précédent : 001604; suivant : 001606The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Auteurs : Alain Saraux [France]Source :
- Autoimmunity Reviews [ 1568-9972 ] ; 2010-06-30.
Abstract
Conventionnal therapy (moisturizers, pilocarpine, Cevimeline, local Cyclosporine, and hydroxychloroquine) remains the basis for the treatment of primary Sjögren's syndrome (pSS) but they do not modify the course of the disease. Rituximab is currently the most fully evaluated biologics in pSS. Open-label studies suggest that Rituximab is well tolerated (although infusion-related reactions and serum sickness remain possible), induces a rapid depletion of B cells in the blood and salivary glands, and could improve early active pSS or pSS with active extra glandular involvement. Two small double blind randomized studies have been conducted and now published, demonstrating its efficacy on fatigue and sicca syndrome in early disease. Two large double blind studies are currently ongoing or planned: The TEARS study (Tolerance and EfficAcy of Rituximab in primary Sjögren syndrome) in France, is currently including 120 patients having either a recent and active disease and/or at least one extraglandular severe signs. The 'TRACTISS' Study (Anti-B-Cell Therapy In Patients With Primary Sjögren's Syndrome), in UK, will include 100 patients having anti-Ro/La antibodies, reduced basal secretion but an increased salivary flow with stimulation, within 10years of diagnosis, symptomatic oral dryness, fatigue and at least one systemic feature.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000241
- to stream Hal, to step Curation: 000241
- to stream Hal, to step Checkpoint: 000180
- to stream Main, to step Merge: 001607
- to stream Main, to step Curation: 001605
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.</title><author><name sortKey="Saraux, Alain" sort="Saraux, Alain" uniqKey="Saraux A" first="Alain" last="Saraux">Alain Saraux</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-156771" status="OLD"> <orgName>Immunologie et Pathologie</orgName> <orgName type="acronym">EA2216</orgName> <desc> <address> <addrLine>CHU Morvan, 5 Rue Foch, BP 824, 29609 Brest</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation name="EA2216" active="#struct-300314" type="direct"></relation> <relation active="#struct-339539" type="direct"></relation> </listRelation> <tutelles><tutelle name="EA2216" active="#struct-300314" type="direct"><org type="institution" xml:id="struct-300314" status="VALID"> <orgName>Université de Brest</orgName> <orgName type="acronym">UBO</orgName> <desc> <address> <addrLine>Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest</addrLine> <country key="FR"></country> </address> <ref type="url">https://www.univ-brest.fr/</ref> </desc> </org></tutelle><tutelle active="#struct-339539" type="direct"><org type="institution" xml:id="struct-339539" status="INCOMING"> <orgName>IFR148</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01150503</idno><idno type="halId">hal-01150503</idno><idno type="halUri">https://hal.archives-ouvertes.fr/hal-01150503</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01150503</idno><date when="2010-06-30">2010-06-30</date><idno type="wicri:Area/Hal/Corpus">000241</idno><idno type="wicri:Area/Hal/Curation">000241</idno><idno type="wicri:Area/Hal/Checkpoint">000180</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000180</idno><idno type="wicri:doubleKey">1568-9972:2010:Saraux A:the:point:on</idno><idno type="wicri:Area/Main/Merge">001607</idno><idno type="wicri:Area/Main/Curation">001605</idno><idno type="wicri:Area/Main/Exploration">001605</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.</title><author><name sortKey="Saraux, Alain" sort="Saraux, Alain" uniqKey="Saraux A" first="Alain" last="Saraux">Alain Saraux</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-156771" status="OLD"> <orgName>Immunologie et Pathologie</orgName> <orgName type="acronym">EA2216</orgName> <desc> <address> <addrLine>CHU Morvan, 5 Rue Foch, BP 824, 29609 Brest</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation name="EA2216" active="#struct-300314" type="direct"></relation> <relation active="#struct-339539" type="direct"></relation> </listRelation> <tutelles><tutelle name="EA2216" active="#struct-300314" type="direct"><org type="institution" xml:id="struct-300314" status="VALID"> <orgName>Université de Brest</orgName> <orgName type="acronym">UBO</orgName> <desc> <address> <addrLine>Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest</addrLine> <country key="FR"></country> </address> <ref type="url">https://www.univ-brest.fr/</ref> </desc> </org></tutelle><tutelle active="#struct-339539" type="direct"><org type="institution" xml:id="struct-339539" status="INCOMING"> <orgName>IFR148</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></analytic><series><title level="j">Autoimmunity Reviews</title><idno type="ISSN">1568-9972</idno><imprint><date type="datePub">2010-06-30</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"> <p>Conventionnal therapy (moisturizers, pilocarpine, Cevimeline, local Cyclosporine, and hydroxychloroquine) remains the basis for the treatment of primary Sjögren's syndrome (pSS) but they do not modify the course of the disease. Rituximab is currently the most fully evaluated biologics in pSS. Open-label studies suggest that Rituximab is well tolerated (although infusion-related reactions and serum sickness remain possible), induces a rapid depletion of B cells in the blood and salivary glands, and could improve early active pSS or pSS with active extra glandular involvement. Two small double blind randomized studies have been conducted and now published, demonstrating its efficacy on fatigue and sicca syndrome in early disease. Two large double blind studies are currently ongoing or planned: The TEARS study (Tolerance and EfficAcy of Rituximab in primary Sjögren syndrome) in France, is currently including 120 patients having either a recent and active disease and/or at least one extraglandular severe signs. The 'TRACTISS' Study (Anti-B-Cell Therapy In Patients With Primary Sjögren's Syndrome), in UK, will include 100 patients having anti-Ro/La antibodies, reduced basal secretion but an increased salivary flow with stimulation, within 10years of diagnosis, symptomatic oral dryness, fatigue and at least one systemic feature.</p> </div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Saraux, Alain" sort="Saraux, Alain" uniqKey="Saraux A" first="Alain" last="Saraux">Alain Saraux</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001605 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001605 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Hal:hal-01150503
|texte= The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
}}
| This area was generated with Dilib version V0.6.33. |  |